Top View
- Status and Challenges of Plant-Anticancer Compounds in Cancer Treatment
- Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
- Assessment of the Applicability of Integrative Tumor Response
- Customs Tariff - Schedule Xxi - 1
- Analysis of Chemotherapeutic Response Heterogeneity and Drug Clustering Based on Mechanism of Action Using an in Vitro Assay
- Clinical Efficacy of Belotecan (CKD-602)
- Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma
- Natural Products and Synthetic Analogs As a Source of Antitumor Drugs
- Molecular Blueprints for Antitumor Drugs
- Part III: Anticancer Agents Antibiotics
- Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: a Retrospective Single-Center Study of Camptothecin Analogs
- Oncology Drugs in the Pipeline
- Practice Guidelines for Management of Ovarian Cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement
- International Patent Classification
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- An Open Access Database of Licensed Cancer Drugs Pan Pantziarka 1,2, §, Rica Capistrano 1, Arno De Potter 3, Liese Vandeborne 1, Gauthier Bouche 1
- Medicines & Vaccines in Development for Cancer
- ( 12 ) United States Patent ( 10 ) Patent No.: US 10,610,125 B2 Dang Et Al
- Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer
- ATP-Based Chemotherapy Response Assay in Primary Or Recurrent Ovarian and Peritoneal Cancer
- A Phase I and Pharmacologic Study of Belotecan in Combination with Cisplatin in Patients with Previously Untreated Extensive-Sta
- CKD-602, a Topoisomerase I Inhibitor, Induces Apoptosis and Cell-Cycle
- Systematic Review of the First-Line Chemotherapy for Chemo-Naïve Extensive-Stage Small-Cell Lung Cancer: Network Meta-Analysis